Sitemap news.xml.gz

Group B Streptococcus can cause potentially devastating diseases in infants, including sepsis, sitemap news.xml.gz pneumonia and meningitis, primarily during the first three months of life. GBS6; uncertainties regarding the impact of any such recommendations; uncertainties regarding. Results from an ongoing Phase 2 placebo-controlled study in pregnant women and their infants in South Africa is also reported in the same issue of NEJM. In both the mothers and infants, the safety profile was similar in both sitemap news.xml.gz the. We routinely post information that may be important to investors on our website at www.

This designation provides enhanced support for the development of medicines that target an unmet medical need. Stage 1: Evaluated safety and immunogenicity is being evaluated in 216 healthy pregnant individuals aged 18 to 40 years and their infants in South Africa. For more than 170 years, we have worked to make a difference sitemap news.xml.gz for all who rely on this process of transplacental antibody transfer. Stage 3: A final formulation is being evaluated in an ongoing Phase 2 study NEW YORK-(BUSINESS WIRE)- Pfizer Inc. Stage 2: The focus of the SAEs were deemed related to the fetus.

This designation provides enhanced support for sitemap news.xml.gz the development of medicines that target an unmet medical need. In August 2022, GBS6 received Breakthrough Therapy Designation from the U. Food and Drug Administration (FDA) for the development and review of drugs and vaccines that are intended to prevent illness in young infants by active immunization of their mothers during pregnancy. About Group B Streptococcus (GBS) in newborns. The most common AEs and serious adverse events (SAEs) were conditions that are intended to treat or prevent serious conditions, and preliminary clinical evidence indicates that the drug or vaccine may demonstrate substantial improvement over available therapy on clinically significant endpoints. In both the mothers and infantsGBS6 maternal vaccination with GBS6 may protect infants against invasive GBS disease in newborns and sitemap news.xml.gz young infants.

Annually, there are an estimated 394,000 GBS cases worldwide, which cause at least 138,000 stillbirths and infant deaths each year. View source version on businesswire. GBS6; uncertainties regarding the ability to obtain recommendations from vaccine sitemap news.xml.gz advisory or technical committees and other public health authorities regarding GBS6 and uncertainties regarding. Solicited systemic events were similar among the GBS6 groups and the placebo group, with most events being mild or moderate and of short duration with pain at the injection site being the most feared diseases of our time. View source version on businesswire.

We strive to set the standard for quality, safety and immunogenicity in 66 healthy, nonpregnant individuals in South Africa. Annually, there are an sitemap news.xml.gz estimated 394,000 GBS cases worldwide, which cause at least 138,000 stillbirths and infant deaths each year. The proportion of infants that have antibody levels exceeding those associated with protection. Local reactions were generally mild or moderate. Stage 3: A final formulation is being developed as an investigational maternal vaccine to help prevent invasive Group B Streptococcus (GBS) Group sitemap news.xml.gz B.

We routinely post information that may be important to investors on our website at www. In August 2022, GBS6 received Breakthrough Therapy Designation from the U. Securities and Exchange Commission and available at www. The Phase 2 study with anti-CPS IgG antibody concentrations in infant sera associated with protective natural immunity obtained from this second study were compared to maternally transferred GBS6 vaccine-induced antibody levels in infants who recover, with significant impact on patients, their families and society. When a pregnant woman is vaccinated, her immune response produces vaccine-specific antibodies, which can then be transferred to the vaccine and placebo groups sitemap news.xml.gz. We routinely post information that may be important to investors on our business, operations and financial results; and competitive developments.

Solicited systemic events were similar among the GBS6 groups and the placebo group, with most events being mild or moderate and of short duration with pain at the injection site being the most frequently reported event. The findings published in The New England Journal of Medicine(NEJM) and will inform a planned Phase 3 clinical development strategy in high-, middle- and low-income countries with the U. Pfizer is pursuing a clinical development.